Index RUT
P/E -
EPS (ttm) -6.07
Insider Own 14.63%
Shs Outstand 30.43M
Perf Week -0.60%
Market Cap 754.93M
Forward P/E -
EPS next Y -6.40
Insider Trans 5.15%
Shs Float 25.98M
Perf Month 11.71%
Income -165.66M
PEG -
EPS next Q -1.55
Inst Own 98.19%
Short Float 25.84%
Perf Quarter -30.26%
Sales 57.17M
P/S 13.21
EPS this Y 1.24%
Inst Trans 18.76%
Short Ratio 15.43
Perf Half Y 5.89%
Book/sh 2.77
P/B 8.95
EPS next Y -6.56%
ROA -33.78%
Short Interest 6.71M
Perf Year 54.48%
Cash/sh 14.14
P/C 1.76
EPS next 5Y -
ROE -161.81%
52W Range 15.78 - 41.31
Perf YTD 15.83%
Dividend Est. -
P/FCF -
EPS past 5Y -19.45%
ROI -36.85%
52W High -39.94%
Beta -0.13
Dividend TTM -
Quick Ratio 10.23
Sales past 5Y 172.96%
Gross Margin 95.80%
52W Low 57.22%
ATR (14) 2.01
Dividend Ex-Date -
Current Ratio 10.23
EPS Y/Y TTM -12.12%
Oper. Margin -245.01%
RSI (14) 52.19
Volatility 10.74% 8.11%
Employees 117
Debt/Eq 4.35
Sales Y/Y TTM 282.17%
Profit Margin -289.75%
Recom 1.50
Target Price 55.30
Option/Short Yes / Yes
LT Debt/Eq 4.33
EPS Q/Q 19.10%
Payout -
Rel Volume 1.52
Prev Close 23.66
Sales Surprise 265.83%
EPS Surprise 30.78%
Sales Q/Q 804.67%
Earnings Nov 05 AMC
Avg Volume 435.07K
Price 24.81
SMA20 11.23%
SMA50 -9.12%
SMA200 -10.74%
Trades
Volume 660,214
Change 4.86%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-02-24 Downgrade
BTIG Research
Buy → Neutral
Jul-22-24 Initiated
H.C. Wainwright
Buy
$55
Jul-19-24 Upgrade
JP Morgan
Neutral → Overweight
$29 → $69
Apr-16-24 Initiated
Leerink Partners
Outperform
$47
Apr-11-24 Initiated
Wells Fargo
Overweight
$56
Mar-12-24 Upgrade
Wedbush
Neutral → Outperform
$20 → $34
Feb-26-24 Initiated
BTIG Research
Buy
$55
Feb-21-24 Initiated
Stifel
Buy
$50
Feb-16-24 Initiated
Piper Sandler
Overweight
$80
May-22-23 Upgrade
JP Morgan
Underweight → Neutral
$31 → $30
May-18-23 Initiated
TD Cowen
Outperform
Jan-06-23 Downgrade
Raymond James
Outperform → Mkt Perform
Nov-01-22 Upgrade
Guggenheim
Neutral → Buy
$44
Sep-19-22 Resumed
H.C. Wainwright
Buy
$35
Sep-13-22 Downgrade
Truist
Buy → Hold
$50 → $28
Sep-01-22 Initiated
Raymond James
Outperform
$35
Mar-22-22 Downgrade
Guggenheim
Buy → Neutral
Jun-22-21 Initiated
H.C. Wainwright
Buy
$43
May-21-21 Initiated
UBS
Neutral
$29
Mar-16-21 Upgrade
Truist
Hold → Buy
Show Previous Ratings
Nov-25-24 09:40AM
Nov-08-24 12:00PM
09:35AM
Nov-05-24 05:30PM
04:15PM
04:15PM
Loading…
04:15PM
Aug-29-24 09:15AM
Aug-23-24 07:26AM
Aug-14-24 04:11PM
(Investor's Business Daily)
-6.35%
10:05AM
(Investor's Business Daily)
05:00AM
Aug-05-24 09:54PM
05:55PM
04:15PM
Jul-29-24 10:00AM
02:53PM
Loading…
Jul-22-24 02:53PM
May-09-24 05:45PM
04:15PM
04:10PM
04:05PM
May-02-24 10:01AM
May-01-24 04:51AM
Apr-24-24 09:00AM
Apr-15-24 02:19PM
Apr-12-24 07:00PM
Apr-09-24 02:40PM
Mar-14-24 12:00PM
09:55AM
Mar-11-24 05:30PM
04:15PM
09:15AM
Loading…
Feb-29-24 09:15AM
Feb-28-24 10:00AM
Feb-22-24 04:00AM
Feb-19-24 05:54AM
Jan-31-24 09:15AM
Jan-12-24 03:02PM
Dec-07-23 09:55AM
Nov-27-23 04:15PM
Nov-14-23 09:35AM
Nov-07-23 04:15PM
Nov-04-23 05:41AM
Nov-02-23 04:15PM
Nov-01-23 09:15AM
Oct-11-23 09:15AM
Oct-09-23 08:27AM
08:15AM
08:05AM
08:00AM
Sep-19-23 03:01PM
Sep-18-23 04:15PM
Sep-12-23 09:15AM
Aug-07-23 04:15PM
Jul-31-23 01:34PM
Jul-04-23 06:22AM
May-30-23 04:15PM
May-24-23 06:01AM
May-22-23 01:44AM
May-11-23 05:35PM
04:15PM
May-04-23 09:55AM
May-02-23 09:15AM
Apr-30-23 09:47AM
Apr-27-23 10:02AM
Apr-26-23 10:02AM
Apr-14-23 03:13AM
Apr-06-23 04:15PM
Apr-03-23 07:14AM
Mar-27-23 06:50PM
Mar-01-23 05:45PM
04:05PM
Feb-27-23 04:05PM
Jan-13-23 09:00AM
Jan-05-23 04:05PM
Dec-22-22 09:33AM
Dec-02-22 09:00AM
Nov-21-22 01:56PM
Nov-11-22 05:19AM
Nov-09-22 02:10PM
Nov-08-22 05:55PM
04:05PM
Oct-25-22 06:28AM
Oct-13-22 09:55AM
Oct-06-22 11:02AM
Oct-05-22 11:31AM
09:00AM
Sep-26-22 08:00AM
Sep-19-22 02:02PM
Sep-14-22 06:14AM
Sep-12-22 11:18AM
07:30AM
Sep-02-22 01:41PM
Sep-01-22 09:58AM
Aug-31-22 04:15PM
Aug-10-22 06:28AM
Aug-08-22 05:35PM
04:05PM
Aug-05-22 04:00PM
Jul-08-22 07:22AM
Jun-24-22 06:31AM
Jun-02-22 04:05PM
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
RENTON HOLLINGS Director Nov 29 '24 Option Exercise 6.93 10,000 69,300 11,950 Dec 03 04:35 PM RENTON HOLLINGS Director Nov 29 '24 Sale 25.00 10,000 250,000 1,950 Dec 03 04:35 PM HOLLINGS C RENTON Director Nov 29 '24 Proposed Sale 25.00 10,000 250,000 Nov 29 01:29 PM Lizzul Paul F. Chief Medical Officer Sep 23 '24 Option Exercise 18.50 1,500 27,750 16,898 Sep 24 04:18 PM Lizzul Paul F. Chief Medical Officer Sep 23 '24 Sale 38.67 1,500 58,005 15,398 Sep 24 04:18 PM PAUL F LIZZUL Officer Sep 23 '24 Proposed Sale 38.67 1,500 58,005 Sep 23 04:16 PM Orwin John A Director Sep 15 '24 Option Exercise 0.00 1,300 0 3,335 Sep 17 06:45 PM LOUMEAU ERIC J CHIEF LEGAL OFFICER Sep 16 '24 Option Exercise 14.02 5,000 70,100 13,520 Sep 17 06:44 PM LOUMEAU ERIC J CHIEF LEGAL OFFICER Sep 14 '24 Option Exercise 0.00 6,000 0 10,740 Sep 17 06:44 PM LOUMEAU ERIC J CHIEF LEGAL OFFICER Sep 16 '24 Sale 39.82 8,720 347,270 7,020 Sep 17 06:44 PM LOUMEAU ERIC J CHIEF LEGAL OFFICER Sep 17 '24 Sale 38.41 3,780 145,191 3,240 Sep 17 06:44 PM Lizzul Paul F. Chief Medical Officer Sep 16 '24 Sale 38.93 2,220 86,425 15,398 Sep 17 06:42 PM MULROY DENNIS CHIEF FINANCIAL OFFICER Sep 16 '24 Option Exercise 20.16 10,000 201,600 14,744 Sep 17 06:41 PM MULROY DENNIS CHIEF FINANCIAL OFFICER Sep 16 '24 Sale 39.91 12,220 487,725 4,744 Sep 17 06:41 PM ERIC J LOUMEAU Officer Sep 17 '24 Proposed Sale 38.41 3,780 145,191 Sep 17 04:02 PM DENNIS MULROY Officer Sep 16 '24 Proposed Sale 40.13 10,000 401,300 Sep 16 04:33 PM ERIC J LOUMEAU Officer Sep 16 '24 Proposed Sale 40.13 6,500 260,845 Sep 16 04:22 PM Lizzul Paul F. Chief Medical Officer Aug 14 '24 Option Exercise 18.50 2,000 37,000 13,618 Aug 16 04:09 PM Lizzul Paul F. Chief Medical Officer Aug 14 '24 Sale 40.00 2,000 80,000 11,618 Aug 16 04:09 PM EcoR1 Capital, LLC 10% Owner Aug 14 '24 Buy 36.50 273,972 9,999,978 7,794,996 Aug 16 12:04 PM PAUL F LIZZUL Officer Aug 14 '24 Proposed Sale 40.00 2,000 80,000 Aug 14 04:34 PM Lizzul Paul F. Chief Medical Officer Jul 18 '24 Option Exercise 18.50 1,500 27,750 13,118 Jul 19 08:35 PM Lizzul Paul F. Chief Medical Officer Jul 18 '24 Sale 35.00 1,500 52,500 11,618 Jul 19 08:35 PM RENTON HOLLINGS Director Jul 15 '24 Option Exercise 6.93 10,000 69,300 11,950 Jul 17 04:45 PM RENTON HOLLINGS Director Jul 15 '24 Sale 30.64 10,000 306,422 1,950 Jul 17 04:45 PM FENTON DENNIS M Director Jun 21 '24 Sale 23.17 1,950 45,182 1,950 Jun 24 05:23 PM FENTON DENNIS M Director Jun 15 '24 Option Exercise 0.00 3,900 0 3,900 Jun 18 08:18 PM Marquet Magda Director Jun 15 '24 Option Exercise 0.00 3,900 0 3,900 Jun 18 08:17 PM Schmid John P. Director Jun 15 '24 Option Exercise 0.00 3,900 0 3,900 Jun 18 08:17 PM Ware J. Anthony Director Jun 15 '24 Option Exercise 0.00 3,900 0 7,500 Jun 18 08:16 PM Orwin John A Director Jun 15 '24 Option Exercise 0.00 2,035 0 2,035 Jun 18 08:15 PM RENTON HOLLINGS Director Jun 15 '24 Option Exercise 0.00 3,900 0 3,900 Jun 18 08:15 PM RENTON HOLLINGS Director Jun 18 '24 Sale 23.16 1,950 45,162 1,950 Jun 18 08:15 PM Jain Rita Director Jun 15 '24 Option Exercise 0.00 4,534 0 4,534 Jun 18 08:14 PM MULROY DENNIS CHIEF FINANCIAL OFFICER May 22 '24 Sale 23.72 1,500 35,580 964 May 24 04:12 PM Faga Daniel CEO Mar 22 '24 Sale 22.78 145,940 3,325,185 752,087 Mar 26 08:10 PM Faga Daniel CEO Mar 25 '24 Sale 21.42 3,000 64,268 749,087 Mar 26 08:10 PM LOUMEAU ERIC J CHIEF LEGAL OFFICER Feb 16 '24 Option Exercise 14.02 5,000 70,100 8,240 Feb 21 05:38 PM LOUMEAU ERIC J CHIEF LEGAL OFFICER Feb 16 '24 Sale 25.00 5,000 125,000 3,240 Feb 21 05:38 PM MULROY DENNIS CHIEF FINANCIAL OFFICER Jan 30 '24 Sale 23.63 3,065 72,425 964 Feb 01 05:27 PM Lizzul Paul F. Chief Medical Officer Jan 06 '24 Option Exercise 0.00 6,145 0 12,672 Jan 09 07:08 PM Lizzul Paul F. Chief Medical Officer Jan 08 '24 Sale 21.81 2,554 55,703 10,118 Jan 09 07:08 PM LOUMEAU ERIC J Chief Legal Officer Jan 06 '24 Option Exercise 0.00 5,545 0 5,545 Jan 09 07:07 PM LOUMEAU ERIC J Chief Legal Officer Jan 08 '24 Sale 21.81 2,305 50,272 3,240 Jan 09 07:07 PM MULROY DENNIS Chief Financial Officer Jan 06 '24 Option Exercise 0.00 5,245 0 6,209 Jan 09 07:06 PM MULROY DENNIS Chief Financial Officer Jan 08 '24 Sale 21.81 2,180 47,546 4,029 Jan 09 07:06 PM Faga Daniel CEO Jan 06 '24 Option Exercise 0.00 17,850 0 904,893 Jan 09 07:05 PM Faga Daniel CEO Jan 08 '24 Sale 21.81 6,866 149,747 898,027 Jan 09 07:05 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite